{
    "root": "646ca48a-403a-0ef0-0fc2-a5569c5b70fd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "venlafaxine hydrochloride",
    "value": "20250326",
    "ingredients": [
        {
            "name": "VENLAFAXINE HYDROCHLORIDE",
            "code": "7D7RX5A8MO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9944"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "METHYLENE CHLORIDE",
            "code": "588X2YUY0A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17996"
        },
        {
            "name": "METHYL ALCOHOL",
            "code": "Y4S76JWI15",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29309"
        },
        {
            "name": "ETHYLCELLULOSES",
            "code": "7Z8S9VYZ4B",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11228"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        }
    ],
    "indications": {
        "text": "venlafaxine hydrochloride extended-release capsules areindicated adults treatment : major depressive disorder ( mdd ) [ ( 14.1 ) ] generalized anxiety disorder ( gad ) [ ( 14.2 ) ] social anxiety disorder ( sad ) [ ( 14.3 ) ] panic disorder ( pd ) [ ( 14.4 ) ]",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "indication starting dose target dose maximum dose mdd ( 2.2 ) 37.5 75 mg/day 75 mg/day 225 mg/day gad ( 2.3 ) 37.5 75 mg/day 75 mg/day 225 mg/day sad ( 2.4 ) 75 mg/day 75 mg/day 75 mg/day pd ( 2.5 ) 37.5 mg/day 75 mg/day 225 mg/day \u2022 take daily food . capsules taken whole ; divide , crush , chew , dissolve ( 2.1 ) . \u2022 discontinuing treatment , reduce dose gradually ( 2.10 , 5.7 ) . . \u2022 renal impairment : reduce total daily dose 25 % 50 % patients renal impairment . reduce total daily dose 50 % patients undergoing dialysis severe renal impairment ( 2.9 ) . . \u2022 hepatic impairment : reduce daily dose 50 % patients mild moderate hepatic impairment . patients severe hepatic impairment hepatic cirrhosis , may necessary reduce dose 50 % ( 2.8 ) .",
        "doid_entities": [
            {
                "text": "cirrhosis (DOID:5082)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5082"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "venlafaxine hydrochloride extended-release capsules usp available containing 37.5 mg , 75 mg 150 mg venlafaxine . 37.5 mg capsules white off-white colored pellets filled hard gelatin capsule grey opaque colored cap pink opaque colored body imprinted \u2018 vfh \u2019 cap \u2018 37.5 \u2019 body black ink . free physical defects supplied bottles 30 \u2019 , 90 \u2019 s,1000 \u2019 . bottles 30 ndc 43598-999-30 bottles 90 ndc 43598-999-90 bottles 1000 ndc 43598-999-10 75 mg capsules white off-white colored pellets filled hard gelatin capsule pink opaque colored cap pink opaque colored body imprinted \u2018 vfh \u2019 cap \u2018 75 \u2019 body black ink . free physical defects supplied bottles 30 \u2019 , 90 \u2019 s,1000 \u2019 . bottles 30 ndc 43598-001-30bottles 90 ndc 43598-001-90 bottles 1000 ndc 43598-001-10 150 mg capsules white off-white colored pellets filled hard gelatin capsule sweedish orange opaque colored cap sweedish orange opaque colored body imprinted \u2018 vfh \u2019 cap \u2018 150 \u2019 body white ink . free physical defects supplied bottles 30 \u2019 , 90 \u2019 , 500 \u2019 . bottles 30 ndc 43598-002-30bottles 90 ndc 43598-002-90 bottles 500 ndc 43598-002-05 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; [ usp controlled room temperature ] .",
    "adverseReactions": "venlafaxine hydrochloride extended-release capsules contraindicated patients : known hypersensitivity venlafaxine hydrochloride , desvenlafaxine succinate excipients formulation [ ( 6.2 ) ] . taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) risk serotonin syndrome [ ( 2.11 ) , ( 5.2 ) , ( 7.1 ) ] .",
    "indications_original": "Venlafaxine hydrochloride extended-release capsules areindicated in adults for the treatment of:\n                  \n                      Major\u00a0Depressive\u00a0Disorder\u00a0(MDD)\u00a0[see\u00a0Clinical\u00a0Studies(14.1)]\n                     Generalized\u00a0Anxiety\u00a0Disorder\u00a0(GAD)\u00a0[see\u00a0Clinical\u00a0Studies(14.2)]\n                     Social\u00a0Anxiety\u00a0Disorder\u00a0(SAD)\u00a0[see\u00a0Clinical\u00a0Studies (14.3)]\n                     Panic\u00a0Disorder\u00a0(PD)\u00a0[see\u00a0Clinical\u00a0Studies\u00a0(14.4)]",
    "contraindications_original": "Indication Starting Dose Target Dose Maximum Dose MDD (2.2) 37.5 to 75 mg/day 75 mg/day 225 mg/day GAD (2.3) 37.5 to 75 mg/day 75 mg/day 225 mg/day SAD (2.4) 75 mg/day 75 mg/day 75 mg/day PD (2.5) 37.5 mg/day 75 mg/day 225 mg/day \u2022 Take once daily with food. Capsules should be taken whole; do not divide, crush, chew, or dissolve ( 2.1 ). \u2022 When discontinuing treatment, reduce the dose gradually ( 2.10 , 5.7 ). . \u2022 Renal impairment: reduce the total daily dose by 25% to 50% in patients with renal impairment. Reduce the total daily dose by 50% or more in patients undergoing dialysis or with severe renal impairment ( 2.9 ). . \u2022 Hepatic impairment: reduce the daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment or hepatic cirrhosis, it may be necessary to reduce the dose by more than 50% ( 2.8 ).",
    "warningsAndPrecautions_original": "Venlafaxine hydrochloride extended-release capsules USP are available containing 37.5 mg, 75 mg or 150 mg of venlafaxine.\n                  \n                     37.5 mg capsules are white to off-white colored pellets filled in hard gelatin capsule with grey opaque colored cap and pink opaque colored body imprinted \u2018VFH\u2019 on cap and \u201837.5\u2019 on body with black ink. Free from Physical defects and are supplied in bottles of 30\u2019s, 90\u2019s,1000\u2019s.\u00a0\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0NDC 43598-999-30 Bottles of 90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0NDC 43598-999-90 Bottles of 1000\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 43598-999-10\n                  \n                  \n                     75 mg capsules are white to off-white colored pellets filled in hard gelatin capsule with pink opaque colored cap and pink opaque colored body imprinted \u2018VFH\u2019 on cap and \u201875\u2019on body with black ink. Free from Physical defects and are supplied in bottles of 30\u2019s, 90\u2019s,1000\u2019s.\u00a0\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0NDC 43598-001-30Bottles of 90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0NDC 43598-001-90 Bottles of 1000\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 43598-001-10\u00a0\n                  \n                  \n                     150 mg capsules are white to off-white colored pellets filled in hard gelatin capsule with sweedish orange opaque colored cap and sweedish orange opaque colored body imprinted \u2018VFH\u2019 on cap and \u2018150\u2019 on body with white ink. Free from Physical defects and are supplied in bottles of 30\u2019s, 90\u2019s, 500\u2019s.\u00a0\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0NDC 43598-002-30Bottles of 90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0NDC 43598-002-90 Bottles of 500\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0NDC 43598-002-05\n                     \n                  \n                  \n                     Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Venlafaxine hydrochloride extended-release capsules are contraindicated in patients:\n                  \n                     with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation [see Adverse Reactions (6.2)]. \n                     taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome [see Dosage and Administration (2.11), Warnings and Precautions (5.2), and Drug Interactions (7.1)].",
    "drug": [
        {
            "name": "venlafaxine hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9944"
        }
    ]
}